Tag - ZVRA

Developments

Zevra highlights publication of positive data from study of MIPLYFFA in NPC

Zevra Therapeutics (NASDAQ: ZVRA) has announced the publication of data suggesting that MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with Niemann-Pick disease type C (NPC) in the peer-reviewed journal...

June 23, 2026

Developments

Zevra receives FDA approval for Miplyffa to treat NPC

Zevra Therapeutics (NASDAQ:ZVRA), has announced FDA approval for its Miplyffa oral capsules, used in combination with miglustat, for the treatment of Niemann-Pick disease C (NPC) in adult and pediatric patients aged two...

September 23, 2024

Tag - ZVRA

Zevra highlights publication of positive data from study of MIPLYFFA in NPC

Zevra receives FDA approval for Miplyffa to treat NPC

Subscribe